13726-16-4

Basic information

• Product Name: 3-CHLORO-4-METHOXYBENZALDEHYDE
• Synonyms: TIMTEC-BB SBB003854;3-CHLORO-4-METHOXYBENZALDEHYDE;3-CHLORO-4-METHOXYBENZENECARBALDEHYDE;3-CHLORO-P-ANISALDEHYDE;AKOS B029259;CHEMBRDG-BB 6945816;3-Methoxy-4-chlorobenzaldehyde
• CAS NO: 13726-16-4
• Molecular Formula: C₈H₇ClO₂
• Molecular Weight: 170.59
• Mol File: 13726-16-4.mol

Chemical Properties

• Melting Point: 56-60 °C(lit.)
• Boiling Point: 265℃
• Flash Point: 118℃
• Appearance: White to pale brown/Powder
• Density: 1.244
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-CHLORO-4-METHOXYBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-4-METHOXYBENZALDEHYDE(13726-16-4)
• EPA Substance Registry System: 3-CHLORO-4-METHOXYBENZALDEHYDE(13726-16-4)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 22-24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 13726-16-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-4-Methoxybenzaldehyde is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new medicinal compounds. Its unique chemical structure allows it to be a key component in creating a variety of drugs.
Used in Fragrance and Flavor Industry:
Leveraging its aromatic properties, 3-Chloro-4-Methoxybenzaldehyde is used as a raw material in the production of fragrances and flavors, adding distinct scents and tastes to various consumer products.
Used in Agrochemical Industry:
3-CHLORO-4-METHOXYBENZALDEHYDE is utilized as a component in the manufacture of agrochemicals, where it plays a role in the development of products designed to enhance agricultural productivity and protect crops.
Used in Dye Industry:
3-Chloro-4-Methoxybenzaldehyde is used as a precursor in the production of dyes, contributing to the coloration of textiles and other materials in the dye industry.

Upstream product

• 189942-81-2 1-chloro-4-dichloromethyl-2-methoxy-benzene 
• 75-89-8 2,2,2-trifluoroethanol 
• 67-56-1 methanol 
• 104-88-1 4-chlorobenzaldehyde 
• 16817-43-9 5-Bromo-2-chloroanisole 
• 97-52-9 2-methoxy-4-nitrophenylamine 
• 1009-36-5 2-chloro-5-nitroanisole 
• 615-74-7 2-chloro-5-methylphenol 
• 73909-16-7 2-chloro-5-methylanisole 
• 85740-98-3 4-chloro-3-methoxybenzoic acid 
• 75-17-2 formaldoxime 
• 13726-14-2 4-chloro-m-anisidine 
• 13726-17-5 (4-chloro-3-methoxyphenyl)methan-1-ol 
• 56962-12-0 3-hydroxy-4-chlorobenzaldehyde 

Downstream Products

• 96495-22-6 2-(4-chloro-3-methoxyphenyl)ethylamine 
• 144181-29-3 N-propionyl-2-(4-chloro-3-methoxyphenyl)ethylamine 
• 144181-30-6 N-(phenylacetyl)-2-(4-chloro-3-methoxyphenyl)ethylamine 
• 144181-31-7 N-<(3-methoxyphenyl)acetyl>-2-(4-chloro-3-methoxyphenyl)ethylamine 
• 144181-32-8 N-<(4-methoxyphenyl)acetyl>-2-(4-chloro-3-methoxyphenyl)ethylamine 
• 144181-33-9 N-<3-(4-methoxyphenyl)propionyl>-2-(4-chloro-3-methoxyphenyl)ethylamine 
• 73898-63-2 1-(4-chloro-3-methoxyphenyl)ethan-1-one 
• 189942-81-2 1-chloro-4-dichloromethyl-2-methoxy-benzene 
• 27572-11-8 1-(4-chloro-3-methoxy-phenyl)propan-2-amine 
• 13726-18-6 1-chloro-4-chloromethyl-2-methoxybenzene 
• 13726-25-5 3-Methoxy-4-chlor-phenylacetylhomoveratrylamin 
• 13726-19-7 2-(4-chloro-3-methoxyphenyl)acetic acid 
• 13726-21-1 2-(4-chloro-3-methoxyphenyl)acetonitrile 
• 873994-89-9 2,4'-dichloro-3,3'-dimethoxy-benzophenone 

Relevant articles and documents

PLATELET ADP RECEPTOR INHIBITORS

no abstract published

Preparation of (2E,4E)-2-(2-benzyloxyethyl)-5-(3-methoxy-4-chlorophenyl) penta-2,4-dienal as a key intermediate in the synthesis of strobilurin B

(2E,4E)-2-(2-Benzyloxyethyl)-5-(4-chloro-3-methoxyphenyl)penta-2,4-dienal was obtained by the condensation of 4-benzyloxybutanal N-tert-butylimine with 4-chloro-3-methoxycinnamic aldehyde with ≥98% configurational purity and 40% yield. When 4-benzyloxy-2-triethylsilylbutanal imine was used, a 7: 3 mixture of the target (2E,4E)-dienal with its (2Z,4E)-isomer was obtained in 60% yield; the latter quantitatively isomerized to the thermodynamically preferable target (2E,4E)-dienal.

Electrochemical methoxylation of some benzaldehyde derivatives at platinum electrode

The electrochemical methoxylation of 4-chlorobenzaldehyde, 4-hydroxybenzatdehyde, 4-anisylaldehyde and 4,4-N,N′- dimethylaminobenzaldehyde was carried out at platinum electrode. Constant potential electrolysis was carried out in undivided electrochemical cell. The reaction is an example of nuclear oxidation of aromatic compounds with substitution. The experimental parameters involved in the reaction are discussed here.

CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of MCP-1 or CCR-2 of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W1, W2, W3, Y, Z, R2, R3, R3

Intermediate compounds and methods for synthesizing chemiluminescent dioxetane substrates

Methods for synthesizing 1,2-dioxetane compounds and intermediate compounds useful in the synthesis of these dioxetane compounds are described. The methods and intermediates allow for the efficient production of dioxetane substrates having electron withdr

NOVEL COMPOUNDS

Novel inhibitors of Rho-kinases are disclosed.

Platelet ADP receptor inhibitors

Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

A new method for the selective oxidation of allylic and benzylic alcohols

A new method is described for the selective oxidation of allylic or benzylic alcohols, in the presence of saturated alcohols, using trimethylamine-N-oxide in the presence of an iron carbonyl.

Combination therapy

The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors or a compound which is an inhibitor of Akt and an inhibitor of a protein kinase, which methods comprise administering to a mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound(s) which are inhibitors of Akt and compound(s) which are inhibitors of protein kinases. The invention also relates to methods of preparing such compositions.

Platelet ADP receptor inhibitors

Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.